BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 21325290)

  • 1. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
    Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
    Avet-Loiseau H; Facon T; Daviet A; Godon C; Rapp MJ; Harousseau JL; Grosbois B; Bataille R
    Cancer Res; 1999 Sep; 59(18):4546-50. PubMed ID: 10493504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
    Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.
    Avet-Loiseau H; Li JY; Morineau N; Facon T; Brigaudeau C; Harousseau JL; Grosbois B; Bataille R
    Blood; 1999 Oct; 94(8):2583-9. PubMed ID: 10515861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
    Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
    Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
    Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
    Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
    Sáez B; Martín-Subero JI; Odero MD; Prosper F; Cigudosa JC; Schoch R; Calasanz MJ; Siebert R
    Oncol Rep; 2007 Nov; 18(5):1099-106. PubMed ID: 17914559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
    Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
    Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
    Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
    Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.
    Miura K; Iida S; Hanamura I; Kato M; Banno S; Ishida T; Kusumoto S; Takeuchi G; Miwa H; Nitta M; Inagaki H; Eimoto T; Nomura K; Taniwaki M; Ueda R
    Cancer Sci; 2003 Apr; 94(4):350-4. PubMed ID: 12824903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights in the clinical biology of multiple myeloma.
    Bataille R
    Semin Hematol; 1997 Jan; 34(1 Suppl 1):23-8. PubMed ID: 9122743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
    Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
    Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
    Nilsson T; Lenhoff S; Rylander L; Höglund M; Turesson I; Mitelman F; Westin J; Johansson B
    Br J Haematol; 2004 Aug; 126(4):487-94. PubMed ID: 15287940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.